FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311748004> ?p ?o ?g. }

• W4311748004 abstract "Abstract Background Serology and PCR testing methods have increased ability to diagnose Bartonella spp. invasive infections. Current treatment recommendations are based primarily on case series and aging data published before newly available diagnostic techniques. These recommendations are limited in safety and effectiveness outcomes. This multicenter, retrospective cohort study describes the epidemiology and treatment outcomes of invasive bartonellosis among patients in the U.S. Methods Collaborating sites were selected from SERGE-45 (Southeastern Research Group Endeavor) research network. Data were collected through REDCap. Subjects were screened from adult patients with invasive bartonellosis diagnosis codes, positive Bartonella spp. serologies, PCR, 16/18S tests, cultures, and Karius® tests from blood or tissue between January 1, 2014, and September 1, 2021. Eligible patients had at least one positive test result, evidence of invasive bartonellosis, and received treatment for bartonellosis. Treatment failure was defined as admission or readmission while on treatment, mortality during treatment or within 30 days after end of treatment, required escalation or extended duration of therapy, premature discontinuation of therapy, or necessitated change in regimen. Those not meeting treatment failure criteria were considered treatment success. Results Of the 169 patients screened, 32 were included, with 19 having treatment success. Bartonella henselae was the most common causative pathogen (n = 31, 97%). Endocarditis was the most common invasive manifestation (n = 18, 56%). Treatment regimens are displayed in Table 1. Primary reasons for treatment failure included necessitated escalation of therapy during treatment course (n = 4, 30.8%) and discontinuation of therapy due to adverse effect (n = 4, 30.8%). Conclusion Doxycycline with rifampin was the most common treatment regimen for invasive bartonellosis, with extended durations used compared to often referenced 6-week courses for invasive infections. It is important to consider adverse drug effects, toxicities, and tolerability in patients being treated for invasive bartonellosis. Disclosures P. Brandon Bookstaver, PharmD, Spero Therapeutics: Advisor/Consultant." @default.
• W4311748004 created "2022-12-28" @default.
• W4311748004 creator A5014794886 @default.
• W4311748004 creator A5038348654 @default.
• W4311748004 creator A5065392289 @default.
• W4311748004 creator A5076528799 @default.
• W4311748004 date "2022-12-01" @default.
• W4311748004 modified "2023-10-14" @default.
• W4311748004 title "338. Epidemiology and Treatment of Invasive <i>Bartonella spp.</i> Infections" @default.
• W4311748004 doi "https://doi.org/10.1093/ofid/ofac492.416" @default.
• W4311748004 hasPublicationYear "2022" @default.
• W4311748004 type Work @default.
• W4311748004 citedByCount "0" @default.
• W4311748004 crossrefType "journal-article" @default.
• W4311748004 hasAuthorship W4311748004A5014794886 @default.
• W4311748004 hasAuthorship W4311748004A5038348654 @default.
• W4311748004 hasAuthorship W4311748004A5065392289 @default.
• W4311748004 hasAuthorship W4311748004A5076528799 @default.
• W4311748004 hasBestOaLocation W43117480041 @default.
• W4311748004 hasConcept C107130276 @default.
• W4311748004 hasConcept C126322002 @default.
• W4311748004 hasConcept C159047783 @default.
• W4311748004 hasConcept C159654299 @default.
• W4311748004 hasConcept C203014093 @default.
• W4311748004 hasConcept C2777535154 @default.
• W4311748004 hasConcept C2778256364 @default.
• W4311748004 hasConcept C2778655176 @default.
• W4311748004 hasConcept C2778715236 @default.
• W4311748004 hasConcept C45189115 @default.
• W4311748004 hasConcept C71924100 @default.
• W4311748004 hasConceptScore W4311748004C107130276 @default.
• W4311748004 hasConceptScore W4311748004C126322002 @default.
• W4311748004 hasConceptScore W4311748004C159047783 @default.
• W4311748004 hasConceptScore W4311748004C159654299 @default.
• W4311748004 hasConceptScore W4311748004C203014093 @default.
• W4311748004 hasConceptScore W4311748004C2777535154 @default.
• W4311748004 hasConceptScore W4311748004C2778256364 @default.
• W4311748004 hasConceptScore W4311748004C2778655176 @default.
• W4311748004 hasConceptScore W4311748004C2778715236 @default.
• W4311748004 hasConceptScore W4311748004C45189115 @default.
• W4311748004 hasConceptScore W4311748004C71924100 @default.
• W4311748004 hasIssue "Supplement_2" @default.
• W4311748004 hasLocation W43117480041 @default.
• W4311748004 hasOpenAccess W4311748004 @default.
• W4311748004 hasPrimaryLocation W43117480041 @default.
• W4311748004 hasRelatedWork W1604612617 @default.
• W4311748004 hasRelatedWork W2278971580 @default.
• W4311748004 hasRelatedWork W2359693886 @default.
• W4311748004 hasRelatedWork W2412539679 @default.
• W4311748004 hasRelatedWork W2587265394 @default.
• W4311748004 hasRelatedWork W2761955893 @default.
• W4311748004 hasRelatedWork W2800298396 @default.
• W4311748004 hasRelatedWork W4211003906 @default.
• W4311748004 hasRelatedWork W4211072461 @default.
• W4311748004 hasRelatedWork W4256740041 @default.
• W4311748004 hasVolume "9" @default.
• W4311748004 isParatext "false" @default.
• W4311748004 isRetracted "false" @default.
• W4311748004 workType "article" @default.